FDA Accepts New Drug Application for Oral Investigational Treatment in RRMM – Bristol Myers Squibb
Bristol Myers Squibb, shared a post on LinkedIn: “The U.S. FDA has accepted a New Drug Application for our second oral investigational treatment option for adult patients with relapsed or […]
Read the full articleYou might also wanna read
FDA Explores Expediting Clinical Trials: Announces Ambitious New Drug Pilot Program
On June 24, 2026, the Food and Drug Administration (FDA) published a notice of availability in the Federal Register requesting information a
FDA Grants Traditional Approval to Selpercatinib for RET-Fusion Solid ...
The FDA has granted traditional approval to selpercatinib for adult and pediatric patients with RET fusion-positive solid tumors post-progre
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced ...
The FDA has granted traditional approval to selpercatinib (Retevmo) for the treatment of adult and pediatric patients 2 years of age and old
FDA Revises Trial Requirements for Drug and Medical Product Approval - Part 2
In part two of this series, Dr. Justin Abbatemarco and Lizzy Lawrence discuss recent FDA guidance, focusing on broader agency changes and ho
Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants
Conditions : Healthy Volunteer Interventions : Drug: Ubrogepant; Drug: Ubrogepant Sponsors : AbbVie Not yet recruiting
FDA-Cleared vs. FDA-Approved : What's the Difference?
If you have ever wondered about the difference between FDA-Cleared versus FDA-Approved LED light therapy devices , then read on for a full e
Comments
Sign in to join the conversation.
No comments yet. Be the first.